R&D Stocks
Pre-commercial enterprises and specialized technology facilitators focus on the high-risk development phase of proprietary intellectual property across biotechnology, energy storage, and industrial infrastructure. These entities operate with high cash burn rates and long-duration capital cycles, relying on milestone achievements or patent breakthroughs to reach commercial viability.
As of Oct 23, 2026, R&D has 145 US-listed companies worth $1T combined. The median member moved +0.4% over the past week; GMAB led among the 25 largest at +18.4% and RGC trailed at -20.0%.
Companies in R&D
- TMO – Thermo Fisher Scientific Inc, $249B
- PFE – Pfizer Inc, $171B
- GSK – GlaxoSmithKline PLC ADR, $103B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- VEEV – Veeva Systems Inc Class A, $52.2B
- ILMN – Illumina Inc, $40.7B
- RVMD – Revolution Medicines Inc, $40.2B
- GMAB – Genmab AS, $26.9B
- LH – Laboratory Corporation of America Holdings, $26.7B
- IFF – International Flavors & Fragrances Inc, $23.9B
- BNTX – BioNTech SE, $22.9B
- CRL – Charles River Laboratories, $16.6B
- EXEL – Exelixis Inc, $16.2B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- IONQ – IONQ Inc, $12.6B
- TECH – Bio-Techne Corp, $11.4B
- PCVX – Vaxcyte Inc, $9.9B
- SYRE – Spyre Therapeutics Inc., $8.7B
- IDCC – InterDigital Inc, $8.6B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- SRRK – Scholar Rock Holding Corp, $5.1B
- RGC – Regencell Bioscience Holdings Ltd, $4.8B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- OLED – Universal Display, $4B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- ALVO – Alvotech, $1.9B
- KMTS – Kestra Medical Technologies, Ltd. Common Stock, $1.7B
- TYRA – Tyra Biosciences Inc, $1.5B
- GHRS – GH Research PLC, $1.3B
- REPL – Replimune Group Inc, $1.3B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- TRAX – First Tracks Biotherapeutics, $1.2B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- MGTX – MeiraGTx Holdings PLC, $955M
- ALMS – Alumis Inc, $885M
- CRVS – Corvus Pharmaceuticals Inc, $876M
- SANA – Sana Biotechnology Inc, $835M
- HELP – Cybin Inc., $799M
- SLDB – Solid Biosciences LLC, $737M
- ACHV – Achieve Life Sciences Inc, $729M
- FDMT – 4D Molecular Therapeutics Inc, $711M
- DNA – Ginkgo Bioworks Holdings, $692M
- PACB – Pacific Biosciences of California, $572M
- VALN – Valneva SE ADR, $527M
- EVO – Evotec SE ADR, $478M
- ARVN – Arvinas Inc, $472M
- ENTX – Entera Bio Ltd, $435M
- NAUT – Nautilus Biotechnology Inc, $412M
- ASMB – Assembly Biosciences Inc, $409M
- EIKN – Eikon Therapeutics, Inc. Common Stock, $408M
- SCTX – Scribe Therapeutics Inc. Common Stock, $380M
- BTQ – BTQ Technologies Corp. Common Stock, $338M
- TTRX – Turn Therapeutics Inc. Common Stock, $337M
- BNTC – Benitec Biopharma Ltd ADR, $335M
- CCCC – C4 Therapeutics Inc, $325M
- IRD – Opus Genetics, Inc., $318M
- CABA – Cabaletta Bio Inc, $251M
- IPSC – Century Therapeutics Inc, $250M
- QSI – QuantumSi Inc, $245M
- LRMR – Larimar Therapeutics Inc, $224M
- IFRX – InflaRx N.V., $223M
- PYXS – Pyxis Oncology Inc, $220M
- LYEL – Lyell Immunopharma Inc, $213M
- LTBR – Lightbridge Corp, $191M
- YARW – Yarrow Bioscience Inc, $183M
- STRO – Sutro Biopharma, $181M
- PEPG – PepGen Ltd, $166M
- NGEN – NervGen Pharma Corp., $166M
- BNR – Burning Rock Biotech Ltd, $158M
- MSLE – Satellos Bioscience Inc. Common Stock, $145M
- CLLS – Cellectis SA, $135M
- AVXL – Anavex Life Sciences Corp, $121M
- SEER – Seer Inc, $121M
- CUE – Cue Biopharma, $117M
- HURA – TuHURA Biosciences Inc, $117M
- PMVP – Pmv Pharmaceuticals Inc, $105M
- MXCT – MaxCyte Inc, $104M
- ANIX – Anixa Biosciences Inc, $101M
- KZIA – Kazia Therapeutics Ltd ADR, $89.7M
- CRBP – Corbus Pharmaceuticals Holding, $85.5M
- VRCA – Verrica Pharmaceuticals Inc, $70.6M
- CSBR – Champions Oncology Inc, $66.9M
- ATHE – Alterity Therapeutics Ltd, $66.8M
- BOLD – Boundless Bio, Inc. Common Stock, $58.5M
- KLRS – Kalaris Therapeutics, Inc., $56.2M
- PLRX – Pliant Therapeutics Inc, $54.7M
- RNTX – Rein Therapeutics Inc, $54.2M
- TENX – Tenax Therapeutics Inc, $50.9M
- ELTX – Elicio Therapeutics Inc., $50.5M
- LASE – Laser Photonics Corporation Common Stock, $41M
- EXOZ – eXoZymes, Inc., $38.3M
- MGX – Metagenomi, Inc. Common Stock, $37.8M
- NSRX – Nasus Pharma Ltd., $37.2M
- CRVO – CervoMed Inc., $35.4M
- FLNA – Filana Therapeutics, Inc., $34M
- IMMP – Immutep Ltd ADR, $32.1M
- CVM – CEL-SCI Corp, $31.5M
- RNAZ – Transcode Therapeutics Inc, $30.1M
- INV – Innventure, Inc., $28.4M
- MIRA – MIRA Pharmaceuticals, Inc. Common Stock, $28M
- NXTC – NextCure Inc, $24.9M
- SHPH – Shuttle Pharmaceuticals Inc, $24.2M
- BYSI – BeyondSpring Inc, $23M
- QNRX – Quoin Pharmaceuticals Ltd DRC, $21.9M
- AKTX – Akari Therapeutics PLC, $21.2M
- PMI – Picard Medical, Inc., $17.2M
- ATYR – aTyr Pharma, Inc., $16.8M
- RADX – Radiopharm Theranostics Limited American Depositary Shares, $15.8M
- ACTU – Actuate Therapeutics, Inc. Common stock, $14.5M
- KTTA – Pasithea Therapeutics Corp, $14M
- ASBP – Aspire BioPharma, Inc., $12.2M
- PHIO – Phio Pharmaceuticals Corp, $10.9M
- PTN – Palatin Technologies, Inc. Common Stock, $9.9M
- SEED – Origin Agritech Ltd, $9.7M
- MTVA – MetaVia Inc., $9.6M
- BCLI – Brainstorm Cell Therapeutics Inc, $9.2M
- CALC – CalciMedica, Inc. Common Stock, $8.7M
- AEMD – Aethlon Medical Inc, $8.5M
- CNSP – CNS Pharmaceuticals Inc, $7.8M
- APRE – Aprea Therapeutics Inc, $7.5M
- SNTI – Senti Biosciences Inc, $7.1M
- MBRX – Moleculin Biotech Inc, $6.3M
- APUS – Apimeds Pharmaceuticals US, Inc., $6.1M
- IMNN – Imunon Inc, $6.1M
- PPCB – Propanc Biopharma, Inc. Common Stock, $4.8M
- NCNA – NuCana PLC, $4.1M
- PMCB – PharmaCyte Biotech Inc, $3.7M
- KALA – Kala Pharmaceuticals Inc, $3.7M
- ERNA – Eterna Therapeutics Inc, $3.7M
- MBIO – Mustang Bio Inc, $3.1M
- OGEN – Oragenics Inc, $1.9M
- MTNB – Matinas BioPharma Holdings Inc, $1.7M
- PTIX – Protagenic Therapeutics, $1.4M
- LABT – Lakewood-Amedex Biotherapeutics Inc. Common Stock, $1.4M
- BNBX – Applied DNA Sciences, Inc., $805,638
- SXTC – China SXT Pharmaceuticals Inc, $676,344
- RBOT – Vicarious Surgical Inc., $392,224
- KRBP – Kiromic Biopharma Inc, $214,931
- SISI – Shineco Inc, $94,564
- SCPX – Scorpius Holdings Inc, $12,228
- CALA – Calithera Biosciences Inc, $487
- TBIO – Telesis Bio Inc., $177